Literature DB >> 8235290

Levels of soluble receptors for tumor necrosis factor type I and type II in paired synovial fluids of arthritis patients.

A M Miltenburg1, D Aderka, J M van Laar, D Wallach, F C Breedveld.   

Abstract

The objective of this study was to determine whether levels of soluble receptors for tumor necrosis factor type I and type II (sTNF-RI and sTNF-RII) as measured in paired synovial fluids (SF) of arthritis patients are associated with clinical or laboratory parameters of local inflammation. sTNF-RI and -RII were measured by ELISA. We found that sTNF-RI and -RII did not correlate with activity of local inflammation. sTNF-RI levels correlated with sTNF-RII concentrations. We concluded that sTNF-RI and -II did not represent markers for local disease activity in arthritis patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235290     DOI: 10.1007/bf00290299

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

1.  Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding.

Authors:  H P Hohmann; R Remy; B Pöschl; A P van Loon
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

2.  The active form of tumor necrosis factor is a trimer.

Authors:  R A Smith; C Baglioni
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

Review 3.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 4.  Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch?

Authors:  C O Jacob
Journal:  Immunol Today       Date:  1992-04

5.  Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation.

Authors:  A M Miltenburg; J M van Laar; R de Kuiper; M R Daha; F C Breedveld
Journal:  Br J Rheumatol       Date:  1991-06

Review 6.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

7.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

8.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

Authors:  D Aderka; H Englemann; V Hornik; Y Skornick; Y Levo; D Wallach; G Kushtai
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

9.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

10.  Isolation and characterization of a tumor necrosis factor binding protein from urine.

Authors:  I Olsson; M Lantz; E Nilsson; C Peetre; H Thysell; A Grubb; G Adolf
Journal:  Eur J Haematol       Date:  1989-03       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.